Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
43.22
+1.02 (2.42%)
Jan 3, 2025, 4:00 PM EST - Market closed
Vera Therapeutics Employees
Vera Therapeutics had 51 employees as of December 31, 2023. The number of employees increased by 5 or 10.87% compared to the previous year.
Employees
51
Change (1Y)
5
Growth (1Y)
10.87%
Revenue / Employee
n/a
Profits / Employee
-$2,634,863
Market Cap
2.74B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 51 | 5 | 10.87% |
| Dec 31, 2022 | 46 | 29 | 170.59% |
| Dec 31, 2021 | 17 | 9 | 112.50% |
| Dec 31, 2020 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
VERA News
- 26 days ago - Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Vera Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - GlobeNewsWire
- 2 months ago - Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - GlobeNewsWire
- 2 months ago - Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years - Benzinga
- 2 months ago - Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 - GlobeNewsWire
- 3 months ago - Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients - Seeking Alpha
- 3 months ago - Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases - GlobeNewsWire